BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 23755122)

  • 1. Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study.
    Maskew M; Fox MP; van Cutsem G; Chu K; Macphail P; Boulle A; Egger M; Africa FI
    PLoS One; 2013; 8(6):e64392. PubMed ID: 23755122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada.
    Dubrow R; Qin L; Lin H; Hernández-Ramírez RU; Neugebauer RS; Leyden W; Althoff KN; Achenbach CJ; Hessol NA; Modur SP; DʼSouza G; Bosch RJ; Grover S; Horberg MA; Kitahata MM; Mayor AM; Novak RM; Rabkin CS; Sterling TR; Goedert JJ; Justice AC; Engels EA; Moore RD; Silverberg MJ;
    J Acquir Immune Defic Syndr; 2017 Aug; 75(4):382-390. PubMed ID: 28394855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era.
    Bohlius J; Valeri F; Maskew M; Prozesky H; Garone D; Sengayi M; Fox MP; Davies MA; Egger M
    Int J Cancer; 2014 Dec; 135(11):2644-52. PubMed ID: 24729433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort study.
    Rohner E; Valeri F; Maskew M; Prozesky H; Rabie H; Garone D; Dickinson D; Chimbetete C; Lumano-Mulenga P; Sikazwe I; Wyss N; Clough-Gorr KM; Egger M; Chi BH; Bohlius J
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):547-54. PubMed ID: 25393941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of immune reconstitution inflammatory syndrome-associated with kaposi sarcoma in mozambique: a prospective study.
    Letang E; Almeida JM; Miró JM; Ayala E; White IE; Carrilho C; Bastos R; Nhampossa T; Menéndez C; Campbell TB; Alonso PL; Naniche D
    J Acquir Immune Defic Syndr; 2010 Apr; 53(5):589-97. PubMed ID: 19801945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK.
    Letang E; Lewis JJ; Bower M; Mosam A; Borok M; Campbell TB; Naniche D; Newsom-Davis T; Shaik F; Fiorillo S; Miro JM; Schellenberg D; Easterbrook PJ
    AIDS; 2013 Jun; 27(10):1603-13. PubMed ID: 23462220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.
    Cornell M; Schomaker M; Garone DB; Giddy J; Hoffmann CJ; Lessells R; Maskew M; Prozesky H; Wood R; Johnson LF; Egger M; Boulle A; Myer L;
    PLoS Med; 2012; 9(9):e1001304. PubMed ID: 22973181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma.
    Tam HK; Zhang ZF; Jacobson LP; Margolick JB; Chmiel JS; Rinaldo C; Detels R
    Int J Cancer; 2002 Apr; 98(6):916-22. PubMed ID: 11948473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa.
    Evans D; Menezes C; Mahomed K; Macdonald P; Untiedt S; Levin L; Jaffray I; Bhana N; Firnhaber C; Maskew M
    AIDS Res Hum Retroviruses; 2013 Jun; 29(6):892-900. PubMed ID: 23373540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study.
    AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord
    Clin Infect Dis; 2017 Oct; 65(8):1316-1326. PubMed ID: 28531260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe.
    Nelson BC; Borok MZ; Mhlanga TO; Makadzange AT; Campbell TB
    Int J Infect Dis; 2013 Oct; 17(10):e902-6. PubMed ID: 23809198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda.
    Ssempijja V; Nakigozi G; Chang L; Gray R; Wawer M; Ndyanabo A; Kasule J; Serwadda D; Castelnuovo B; Hoog AV; Reynolds SJ
    BMC Infect Dis; 2017 Aug; 17(1):582. PubMed ID: 28830382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.
    Rohr JK; Ive P; Horsburgh CR; Berhanu R; Shearer K; Maskew M; Long L; Sanne I; Bassett J; Ebrahim O; Fox MP
    PLoS One; 2016; 11(8):e0161469. PubMed ID: 27548695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.
    Antiretroviral Therapy Cohort Collaboration
    Lancet HIV; 2017 Aug; 4(8):e349-e356. PubMed ID: 28501495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa.
    Nachega JB; Hislop M; Nguyen H; Dowdy DW; Chaisson RE; Regensberg L; Cotton M; Maartens G
    J Acquir Immune Defic Syndr; 2009 May; 51(1):65-71. PubMed ID: 19282780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.
    Fox MP; Sanne IM; Conradie F; Zeinecker J; Orrell C; Ive P; Rassool M; Dehlinger M; van der Horst C; McIntyre J; Wood R
    AIDS; 2010 Aug; 24(13):2041-50. PubMed ID: 20613459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis.
    Ravimohan S; Tamuhla N; Steenhoff AP; Letlhogile R; Makutu DK; Nfanyana K; Rantleru T; Tierney A; Nkakana K; Schwartz AB; Gross R; Macgregor RR; Bellamy SL; Frank I; Weissman D; Bisson GP
    J Infect Dis; 2013 Dec; 208(11):1784-93. PubMed ID: 23908475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-year mortality in adults initiating antiretroviral therapy in South Africa.
    Cornell M; Johnson LF; Wood R; Tanser F; Fox MP; Prozesky H; Schomaker M; Egger M; Davies MA; Boulle A;
    J Int AIDS Soc; 2017 Sep; 20(1):21902. PubMed ID: 28953328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling adverse treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics in Lusaka.
    Fwemba I; Musonda P
    Public Health; 2017 Jun; 147():8-14. PubMed ID: 28404502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in CD4 and viral load testing 2005 to 2018: multi-cohort study of people living with HIV in Southern Africa.
    Zaniewski E; Dao Ostinelli CH; Chammartin F; Maxwell N; Davies MA; Euvrard J; van Dijk J; Bosomprah S; Phiri S; Tanser F; Sipambo N; Muhairwe J; Fatti G; Prozesky H; Wood R; Ford N; Fox MP; Egger M
    J Int AIDS Soc; 2020 Jul; 23(7):e25546. PubMed ID: 32640106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.